Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
High Dose
100%
Phase II Trial
100%
Clinical Efficacy
100%
Platelet-derived Growth Factor Receptor (PDGFR)
100%
Metastatic Melanoma
100%
Imatinib Mesylate
100%
Imatinib
50%
Tumor
33%
Clinical Response
33%
Response Rate
33%
Immunohistochemistry
16%
Tumor Specimens
16%
Phase I Study
16%
Median Overall Survival
16%
Pretreated Patients
16%
Tumor Samples
16%
Advanced Melanoma
16%
Duration of Response
16%
Disease Progression
16%
Progression-free Survival
16%
Signal Transduction
16%
BCR-ABL
16%
Therapeutic Regimen
16%
National Cancer Institute
16%
Malignant Melanoma
16%
Time to Progression
16%
Median Time
16%
Paraffin Embedding
16%
Accruals
16%
Common Toxicity Criteria
16%
Objective Response
16%
Receptor Expression
16%
Systemic Treatment
16%
Oral Tyrosine Kinase Inhibitors
16%
Alternative Treatment Methods
16%
Detection of Envelope Modulation on Noise (DEMON)
16%
Medicine and Dentistry
Phase II Trials
100%
Imatinib
100%
Drug Megadose
100%
Platelet Derived Growth Factor Receptor
100%
Metastatic Melanoma
100%
Neoplasm
33%
Melanoma
33%
Tumor
33%
Cancer
16%
Malignant Neoplasm
16%
Immunohistochemistry
16%
Systemic Therapy
16%
Overall Survival
16%
Progression Free Survival
16%
Receptor Expression
16%
Disease Exacerbation
16%
Kinase
16%
Tyrosine-Kinase Inhibitor
16%
Signal Transduction
16%
Oral
16%
Nursing and Health Professions
Drug Megadose
100%
Platelet Derived Growth Factor Receptor
100%
Imatinib
100%
Metastatic Melanoma
100%
Efficacy
100%
Neoplasm
33%
Melanoma
33%
Staining
33%
Systemic Therapy
16%
Overall Survival
16%
National Health Organization
16%
Progression Free Survival
16%
Disease Exacerbation
16%
Immunohistochemistry
16%
Protein Tyrosine Kinase Inhibitor
16%